论文部分内容阅读
我国中药抗癌研究获重大突破:双向广谱抗癌药“康莱特”注射液显著提高临床疗效,在直接抑杀癌细胞的同时整体性增强机体免疫功能,改变了中药治癌只是辅助用药的传统观点,改写了抗癌中药只能口服的历史,标志着中药创新迈上新台阶。国家中医药管理局今天宣布,这一重大中医药科技成果已实现产业化,达到了年供5万患者使用的生产能力,并在二十多个国家和地区临床应用。
China’s anti-cancer research on Chinese medicine has achieved a major breakthrough: The two-way broad-spectrum anticancer drug “KLT” has significantly improved clinical efficacy, and it can directly enhance the immune function while directly killing cancer cells. It has changed the use of traditional Chinese medicine to treat cancer. The traditional point of view rewrites the history of anti-cancer medicines that can only be taken orally, marking a new stage in the innovation of traditional Chinese medicine. The State Administration of Traditional Chinese Medicine announced today that this major scientific and technological achievements in Chinese medicine has been industrialized, reaching an annual production capacity of 50,000 patients, and has been clinically applied in more than 20 countries and regions.